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Yuzhen Liang,1 Yongrong Lai,1 Paul Schwarzenberger,2 Qiaochuan Li,1 Jie Ma,1 Jun Luo,1
Rongrong Liu,1 Lingling Shi,1 Jicheng Zhou,1 Zhigang Peng,1 Jie Yang,1
Donghong Deng,1 Yizhen Zhou1Although the drug imatinib has been accepted as the treatment of choice for chronic myelogenous leukemia
(CML) in chronic phase (CP) throughout the Western world, allogeneic stem cell transplantation (allo-SCT)
continues to remain a widely practiced first-line treatment in countries with limited health care budgets. The
rationale is not scientific, but largely economically based. We analyzed a cohort of 46 CML patients who
participated in a graft-versus-host disease (GVHD) prophylaxis clinical trial and underwent related HLA-
matched allogeneic peripheral blood stem cell transplantation. The median time of follow-up in surviving pa-
tients was 43 months (range: 4-89 months). Risk stratification of the population was done by European Blood
and Marrow Transplant (EBMT) criteria. The estimated probabilities of overall survival (OS) and leukemia-
free survival (LFS) at 3 years in low EBMTrisk score (0-2) patients were both 91%, respectively. We conclude
that in countries with restricted access to imatinib, allo-SCT should be considered early on as front-line ther-
apy. Continued research support for bone marrow transplantation will be needed to make a global impact on
this disease.
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Chronic myelogenous leukemia (CML) is a myelo-
proliferative disorder, arising from a translocation
t(9;22)(q34;q11) in hematopoietic precursors, known
as the Philadelphia chromosome [1,2]. The fusion
gene (Bcr-Abl) product initiates deregulated cellular
proliferation, which adversely affects differentiation
and blocks apoptosis.
Collectively, this leads to malignant expansion of
pluripotent stem cells in blood forming organs [3].
The annual incidence of CML is 1 to 2 cases per
100,000 adults [3]. The majority of patients
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6/j.bbmt.2010.01.016left untreated, after an average of approximately 3 to
5 years, the disease changes to an accelerated phase,
which inevitably progresses to a fatal acute leukemia,
also known as blast crisis (BC). The median survival
at that point is less than 6 months [4]. Historically, ar-
senic, hydroxyurea, busulfan, radiation, interferon-a,
and stem cell transplantation (SCT) had been devel-
oped as treatments [5]. Until the development of ima-
tinib, treatment was largely palliative, and the only
potentially curative treatment available was allogeneic
SCT (allo-SCT), which carried very high risks of mor-
bidity andmortality [6,7]. Data of EuropeanGroup for
Blood and Marrow Transplantation (EBMT) showed
that the outcome of transplantation has improved
over time with a marked reduction in treatment-
related mortality (TRM) [8]. Five-year event-free sur-
vival (EFS) after an HLA-identical sibling allo-SCT in
CML patients was 70%-80% (CP\1 year after diag-
nosis), 50%-60% (CP .1 year after diagnosis), 30%-
50% (accelerated phase), and 5%-10% (blastic phase),
respectivly [9].
Imatinib mesylate is a specific tyrosine kinase in-
hibitor that blocks theenzymatic activity of the dysre-
gulated Bcr-Abl oncoprotein. The introduction of
this drug has revolutionized the treatment of CML.
It has dramatically improved the overall outcomes of
Biol Blood Marrow Transplant 16:848-853, 2010 849Targeted Agents for CMLCML patients and is generally reasonably well toler-
ated [10,11]. Recently, updated results from
a randomized clinical trial compared imatinib with
interferon-a as a first-line treatment for chronic phase
CML (IRIS study) [12,13]. At 7 years, the estimated
overall survival (OS) and EFS were 86% and 81%,
respectively [14]. The clinical practice guidelines of
the National Comprehensive Cancer Network
(NCCN) (2008) recommends imatinib to be used as
first-line treatment for patients with newly diagnosed
CML. It recommends allo-SCT as second-line treat-
ment after imatinib failure, except for high-risk disease
and for very low transplantation risk, patients’ prefer-
ence, or for economic reasons.
Published results comparing historic data from
allo-SCT for CML clearly favor use of imatinib over
front-line transplant in patients with CP [15,16].
Either form of treatment is very expensive and poses
a major burden on health care systems. However,
given the drug cost for imatinib, in poorer nations or
nations with a limited health care budget, the use of
imatinib can be prohibitive. For instance, the annual
cost for imatinib in China is in U.S. $41,000.
Socially disadvantaged patients may be eligible to
receiving financial help from a government
controlled foundation; however, those patients still
will be responsible for $10,300 per annum.
Considering that in 2008, in China, the annual
income in urban households was approximately
$2310 and $700 in rural households, this is a classic
catch 22, because patients who would be eligible for
the foundation money would not be able to come up
with the residual balance. In contrast, relative to the
United States, the average cost for a related donor
allo-SCT is much cheaper in economically less devel-
oped countries because all such services are rendered
within the system at less cost. In China, the costs for
the procedure are between U.S. $20,000. and 30,000,
which includes follow-up visits and graft-versus-host
dieases (GVHD) medications. That means that the
drug cost for only 1 year of imatinib already substan-
tially exceeds the allo-SCT costs plus follow-up
treatments.
For that reason, in China as well as in many other
non-Western countries whose health care system can-
not afford the use of imatinib, allo-SCT is considered
more cost effective than life-long therapy with imati-
nib [17,18]. Therefore, exclusively for economic
reasons, in China and likely also in other nations, for
transplant-eligible patients allo-SCT remains the
standard first-line treatment of choice for all CML
risk group patients.
As part of a larger prospective cohort study de-
signed to investigate a new GVHD prophylaxis
regimen in patients with related HLA-matched and
single antigen mismatched allogeneic peripheral
blood stem cell transplantation (PBSCT), we treateda cohort of 46 CML patients between June of 2001
and September 2008 [19]. We subanalyzed this co-
hort and compared the outcomes to that of the
IRIS study.DESIGN AND METHODS
Patients and transplantation characteristics are
summarized in Table 1. The data were collected and
analyzed through December 31, 2008. The median
time of follow-up in surviving patients was 43 months
(range: 4-89 months). Risk score was defined following
the EBMT risk score system [20].The patients were
divided into 2 groups: low EBMT risk scores (0-2)
and high EBMT risk scores ($3) patients.
Forty-three patients received cyclophosphamide
(Cy, 60 mg/kg/day 2 days) and busulfan (Bu) as con-
ditioning regimen. Bu was given either orally (4 mg/
kg/day on days 1-4) or intravenously (3.2 mg/kg/day
on days 1-4). Three patients in blastic phase received
cyclophosphamide (Cy, 60 mg/kg/day 2 days) and
total body irradiation (TBI 5.0 Gy/day 2 days) as
conditioning regimen. Patients were infused with
granulocyte-colony stimulating factor (G-CSF) mobi-
lized donor allogeneic mobilized stem cells. The
median numbers of mononuclear cells (MNC) and
CD 341 cells infused were 9.26 (5.46-15.87)  108/
kg and 5.79 (2.57-13.26)  106/kg, respectively.
GVHD prophylaxis consisted of cyclosporine
(CsA), methothexate (MTX), and mycophenolate mo-
fetil (MMF). Intravenous CsA (3 mg mg/kg/day) given
on days 1-30, thereafter orally (6 mg mg/kg/day), with
target trough levels at 200-300 ng/mL. MTX was
administered intravenously at doses of 15 mg/m2 on
day 11 and 10 mg/m2 on days 13, 16, and 111.
MMF was given orally at a dose of 250 mg twice daily
until day 20 and tapered to a maintenance dose of 250
mg to day130. Dose adjustments and supportive care
were administered following standard practice
guidelines.
Statistical Analysis
Both OS and leukemia-free survival (LFS) were
calculated by using the Kaplan-Meier method pro-
vided through the statistical software program SPSS
version 13.0 (SPSS, Chicago, IL, USA). TRM and
mortality rates from disease progression (MDP) were
calculated using the cumulative incidence method pro-
vided through the statistical software program NCSS
2007 (Number Cruncher Statistical System, Kaysville,
UT, USA).RESULTS
The outcomes and the cost of transplantation in 46
patients are summarized in Tables 2 and 3,
Table 1. Patients and Transplantation Characteristics
Characteristic n %
Patients 46
Adult 44 95.6
Pediatric 2 4.3
Male/Female 36/10 78.3/21.7
Median age, years (range) 33 (10-49)
Disease status
CP 36 78.3
AP 4 8.6
BC 6 13.0
Risk score
0-2 34 73.9
$3 12 26.1
HLA status
Identical 41 89.1
1- antigen mismatched 5 10.9
ABO blood group status
Matched 33 71.7
Mismatched 13 28.3
Conditioning regimen
TBI + Cy 3 6.5
Bu + Cy 43 93.5
CML indicates chronic myelogenous leukemia; CP, chronic phase; AP, ac-
celerated phase; BC, blast crisis; HLA, human leukocyte antigen; TBI,
total body irradiation; Cy, cyclophosphamide; Bu, busulfan; Risk score,
EBMTrisk score.
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EBMT risk scores patient achieved engraftment.
Only 7 of 46 patients developed acute GVHD
(aGVHD), 1 of whom developed grade III disease.
No fatality was recorded. The cumulative incidence
of aGVHD was 15.2% (95% confidence interval [CI]
7.7%-30.1%). The cumulative incidence of grade I
aGVHD was 6.5% (95% CI 2.2%-19.5%).The
cumulative incidence of grade II-IV aGVHD was
8.7% (95% CI 3.4%-22.2%). The cumulative inci-
dence of grade III-IV aGVHD was 2.2% (95% CI
0.3%-15.1%). There was no difference in the overall
incidence between low and high EBMT risk score
groups. Sixteen patients (cumulative incidence
35.7%) developed chronic GVHD (cGVHD) with 8
patients (17.9%) having limited and 8 patients
(17.9%) having extensive cGVHD. Here again, no de-
tectable difference in cGVHD was found between risk
groups.
Five patients died free of disease (4 died from infec-
tion and 1 died from graft failure). The cumulative
rates of TRM at 3 years in low EBMT risk score pa-
tients and high EBMT risk score patients were 6.1%
(95% CI 1.6%-23.3%) and 20.0% (95% CI 5.8%-
69.1%) (P 5 .1585), respectively.Table 2. Outcomes at 3 Years in 46 Patients with CML
N 5 46 OS (%)
EBMT risk score
0-2 34 90.8
$3 12 21.2
CML indicates chronic myelogenous leukemia; OS, overall survival; LFS, leukem
disease progression.All patients who engrafted (n5 45) achieved a com-
plete remission (CR). The cumulative rates of MDP at
3 years in low EBMT risk score and high EBMT risk
scores patients were 3.3% (95% CI 0.5%-22.9%)
and 57.8% (95% CI 33.1%-100.0%) (P\ .0001),re-
spectively. One patient who relapsed in CP achieved
another long-lasting (29 months) CR after stopping
the GVHD prophylaxis and subsequent initiation of
imatinib therapy. Three patients who relapsed or pro-
gressed to BC failed rescue with imatinib as well as do-
nor lymphocyte infusion (DLI) therapy.
With a median time of follow-up of 43 months
(range: 4-89months), 34 of 46 patients were alive with-
out disease. The estimated probabilities of OS at 3
years in low EBMT risk score patients and high
EBMT risk score patients were 90.8% (95% CI
80.7%-100.0%) and 21.2% (95% CI 0 %-47.0%) (P
\ .0001), respectively (Figure 1 A). The estimated
probabilities of LFS at 3 years in low EBMT risk
scores patients and high EBMT risk scores patients
were 90.8% (95% CI 80.7%-100.0%) and 18.2%
(95% CI 0 %-40.9%) (P \ .0001), respectively
(Figure 1B).DISCUSSION
In light of the available imatinib data, recommend-
ing allo-SCT for patients with newly diagnosed CML
in CP is an ethical challenge for physicians practicing
in countries that are on a restricted health care budget.
Historically, the only definitive curative therapy for
CML was and remains allo-SCT. Initial outcomes
with allo-SCT in CML was associated with significant
mortality and morbidity, which may have been related
to older techniques as well as transplantations that
were performed predominantly in high-risk patients
as a rescue setting or in patients who already had
been treated conservatively for longer periods. Al-
though much work still needs to be done, during the
past decade, all aspects of SCT have continuously im-
proved. Specifically, progress has been made in HLA
typing, management of infections, supportive care,
conditioning regimens, GVHD prophylaxis, and new
salvage approaches for disease relapse post transplant
[20-24]. Our group previously reported a new
GVHD prophylaxis regimen that effectively
decreased the risk of developing aGVHD. Our data
were compared to international historic data as wellLFS (%) TRM (%) MDP (%)
90.8 6.1 3.3
18.2 20.0 58.7
ia-free survival; TRM, treatment-related mortality; MDP, mortality from
Table 3. The Median Allogeneic Transplantation Costs per
CML Patient at a Chinese Institution (n 5 46)
Category Costs ($)*
The costs of hospitalizations
Pharmacy 13,101 (4,370-25,386)
therapy 2108 (1,026-4081)
Nursing 294 (212-421)
Laboratory 1018 (288-1732)
Blood bank 1017 (455-3247)
Other 2469 (796-3918)
The costs of outpatient visits
and drug treatment†
6539 (3694-32,698)
Total costs 26,432 (18,770-62,039)
CML indicates chronic myelogenous leukemia.
*1 USD56.83 CNY.
†Includes the costs for transplant-related rehospitalizations.
Figure 1. Estimated probabilities of overall survival (OS) (A) and
leukemia-free survival (LFS) (B) at 3 years in low EBMT risk score (0-
2) and high EBMTrisk score ($3) CML patients following allogeneic pe-
ripheral blood SCT (PBSCT) and CsA/MTX/MMF GVHD prophylaxis.
Biol Blood Marrow Transplant 16:848-853, 2010 851Targeted Agents for CMLas data within the Chinese registries [19]. In our series
of 100 patients, the cumulative incidence of grade II-
IV aGVHD was 9.5% [19]. In previously published
studies, GVHD prophylaxis typically consisted of
a combination of CsA and MTX, with cumulative in-
cidence of grade II-IV aGVHD ranging between
37.4% and 65% [25-29]. In comparable settings
within Chinese registries, the incidence of grade II-
IV aGVHD ranged between 21.6% and 40.0% [30-
32]. In a series of 131 CML patients treated with
allo-SCT during first CP using a targeted Bu/Cy pre-
parative regimen reported by Radich et al. [23], the OS
and disease-free survival (DFS) at 3 years were 86%
and 78%, respectively. The outcome of transplanta-
tion is highly dependent on the presence or absence
of certain risk factors, and patient selection for trans-
plantation is critical for the success of the procedure.
Gratwohl et al. [8,20] determined for the EBMT
favorable risk factors: availability of a sibling donor,
younger age of the recipient, female recipient/female
donor, transplantation at first CP, and the time frame
being less than 12 months from the time of diagnosis
to transplant. Patients with EBMT risk scores of 0-2
are expected to have a 85% OS at 5 years [20].
In our study, the estimated probability of OS at 3
years for low EBMT risk scores (0-2) patients was
91%, the LFS was also 91%. The 3 year results are
also not far from the published 7 year IRIS data
achieved with imatinib. Combining the evidence
from the EBMT data [22], Radich’s et al. study [23],
the Mexico experience [17], as well as the data from
our study, a reasonable argument could be made for
considering front-line allo-SCT for situations where
imatinib is not an option. Ruiz-Argu¨elles et al. [17] re-
cently reported the outcomes of 72 CML patients in
first CP (22 patients received a reduced-intensity
allo-SCT, 50 patients received a tyrosine kinase inhib-
itor (TKI), mainly imatinib). The 6-year OS in allo-
SCT and TKI patients were 77% and 84%, respec-
tively (P, NS). Given the global economic crisis, it is
unlikely that the treatment decision tree for CML in
China or other countries with limited health carebudgets will change anytime soon. It also appears
that at least some patients who relapse after transplant
can still be salvaged with imatinib and use of this drug
would likely be rationed for such cases [33,34]. In
health care settings with rationed resources, limiting
the use of imatinib to such rescue settings would
certainly be more cost effective, but only justifiable if
short and long-term toxicities of GVHD can be better
controlled. In a perfect system, the physician would
have the discretion to sequence treatment modalities
based on data rather than economics.
The estimated probabilities of OS and LFS at 3
years in our high EBMT risk scores ($3) patients
were 21.2% and 18.2%, respectively. We feel this
was mainly because transplantation was performed at
advanced stages of their disease. Although the
outcomes are disappointing for high risk patients,
allo-SCT maintains a pivotal role for the treatment
852 Biol Blood Marrow Transplant 16:848-853, 2010Y. Liang et al.of patients at the advanced stage of CML [35]. Other
strategies to improve transplantation outcomes for
advanced stage or high risk CML are being investi-
gated, and all eligible patients should take advantage
of participating in innovative clinical trials. Examples
are pretransplant treatment with TKIs [36,37],
novel conditioning regimens, or biologic response
modification pre- or posttransplant [23,38-40]. Close
monitoring of minimal residual disease (MRD)
followed by early intervention [41] as well as treatment
of relapse posttransplant with donor lymphocyte infu-
sions or TKIs may also extend OS [42-44]. To date,
pretransplant imatinib treatment has not been shown
to have a negative influence on the outcomes of allo-
SCT [45,46].
There continues to be a substantial need for basic
and clinical research to further improve allo-SCT out-
comes, specifically the management of GVHD. Most
of this research is conducted in industrialized nations
with a larger R&D budget. There is growing concern
in other nations that the field of transplantation will
receive less attention because the indications, at least
in the Western world are shrinking, whereas at the
same time in other countries the indications actually
are expanding. Although allo-SCT remains the stan-
dard treatment of choice for newly diagnosed CML
patients in many developing countries, continuous re-
search efforts will be vital to improve outcomes of this
disease worldwide.ACKNOWLEDGMENTS
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